[1]张　维,龙松权,彭印钢.血清CYFRA21-1，HCY 及CA15-3 水平联合检测对乳腺癌辅助诊断的临床评价[J].现代检验医学杂志,2020,35(03):55-57.[doi:10.3969/j.issn.1671-7414.2020.03.013]
　ZHANG Wei,LONG Song-quan,PENG Yin-gang.Clinical Evaluation of Detecting Serum CYFR21-1, HCY and CA15-3 to Assisted Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2020,35(03):55-57.[doi:10.3969/j.issn.1671-7414.2020.03.013]
点击复制

血清CYFRA21-1，HCY 及CA15-3 水平联合检测对乳腺癌辅助诊断的临床评价()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年03期
页码:
55-57
栏目:
论著
出版日期:
2020-07-20

文章信息/Info

Title:
Clinical Evaluation of Detecting Serum CYFR21-1, HCY and CA15-3 to Assisted Diagnosis of Breast Cancer
文章编号:
1671-7414（2020）03-055-04
作者:
张　维;  龙松权;  彭印钢
（桂林市中医医院检验科，广西桂林541002）
Author(s):
ZHANG Wei;  LONG Song-quan;  PENG Yin-gang
（Department of Clinical Laboratory, Guilin Hospital of Traditional Chinese Medicine, Guangxi Guilin 541002, China）
关键词:
乳腺癌; 细胞角蛋白19 片段; 同型半胱氨酸; 糖类抗原15-3
分类号:
R737.9；R730.43
DOI:
10.3969/j.issn.1671-7414.2020.03.013
摘要:
目的　探讨血清细胞角蛋白19 片段（cytokeratin 19 fragment，CYFR21-1）、同型半胱氨酸（homocysteine， HCY）和糖类抗原15-3(carbohydrate antigen 15-3，CA15-3) 在乳腺癌患者体内的表达水平及其在乳腺癌诊断中的 价值。方法　选取2019 年1~11 月期间收治的乳腺癌患者73 例为研究对象，良性乳腺瘤患者95 例为疾病对照组， 同期体检的健康志愿者80 例为正常对照组，分别检测并比较三组研究对象CYFRA21-1，HCY 和CA15-3 水平， 分析其对乳腺癌诊断的价值。结果　乳腺癌组的CYFRA21-1，HCY 和CA15-3 检测水平分别为6.25±1.60ng/ml， 19.42±3.67μmol/L 和40.84±6.77U/ml；良性乳腺瘤组的CYFRA21-1，HCY 和CA15-3 检测水平分别为1.28±0.38 ng/ml，11.72±2.46μmol/L 和16.44±3.71 U/ml；对照组的CYFRA21-1，HCY 和CA15-3 检测水平分别为0.86±0.21 ng/ml，9.57±2.22μmol/L 和12.84±2.69 U/ml，结果显示乳腺癌组的三项指标表达水平明显高于乳腺瘤组和对照 组，差异均有统计学意义（F=22.314~97.593，均P ＜ 0.05）。乳腺癌晚期患者（Ⅲ - Ⅳ期）血清CYFRA21-1， HCY 和CA15-3 水平显著高于早期患者（Ⅰ - Ⅱ期），差异均有统计学意义（t=6.311~11.720, 均P ＜ 0.05）。血清 CYFRA21-1，HCY 和CA15-3 联合检测灵敏度和准确度分别为89.04% 和83.33%，与单项检测比较差异均有统计学 意义（t=2.655~21.196，均P ＜ 0.05）。结论　CYFRA21-1，HCY 和CA15-3 联合检测可明显提高乳腺癌诊断的灵 敏度和准确度，为临床提供经济快捷有效的实验室依据。
Abstract:
Objective　To investigate the expression levels of serum cytokeratin 19 fragment (CYFR21-1), homocysteine (HCY) and carbohydrate antigen 15-3 (CA15-3) in breast cancer patients and their diagnostic value in breast cancer. Methods　A total of 73 breast cancer patients treated in the hospital from January to November 2019 were selected as the research subjects, 95 patients with benign breast tumors were selected as disease control group, and 80 healthy volunteers who underwent physical examination during the same period were selected as healthy control group. The levels of CYFRA21-1, HCY and CA15-3 in three groups of subjects were detected and compared respectively, and their value in the diagnosis of breast cancer wereanalyzed. Results　The serum levels of CYFRA21-1, HCY and CA15- 3 in breast cancer group were 6.25±1.60 ng/ml, 19.42±3.67μmol/L and 40.84±6.77 U/ml, respectively.The serum levels of CYFRA21-1, HCY and CA15-3 in benignbreast tumor group were 1.28±0.38 ng/ml, 11.72±2.46μmol/ L and 16.44±3.71 U/ml,respectively. The serum levels of CYFRA21-1, HCY and CA15-3 in the control group were 0.86±0.21 ng/ml, 9.57±2.22μmol/L and 12.84±2.69 U/ml, respectively.The results showed that the detection levels of all indicators in the breast cancer group were higher than those in the benign breast tumor group and the control group, and the differences were statistically significant (F = 22.314~97.593, all P<0.05).The serum levels of CYFRA21-1, HCY and CA15-3 in patients with advanced breast cancer (stage III-IV) were significantly higher than those in early patients (stage Ⅰ - Ⅱ ), and the difference were statistically significant (t = 6.311~11.720, all P<0.05). The sensitivity and accuracy of the combined detection of serum CYFRA21-1, HCY and CA15-3 were 89.04% and 83.33%, respectively, and the difference were statistically significant compared withthe single test (t=2.655~21.196, all P<0.05). Conclusion　The combined detection of CYFRA21-1, HCY and CA15-3 could significantly improve the sensitivity and accuracy of breast cancer diagnosis, and provide a cost-effective and efficient laboratory basis for clinical practice.

参考文献/References:

[1]　雷巧，陈俊杰，田建．血清F-PSA,PSA,HGH,CA15-3 水平与乳腺癌术后转移的相关性[J]．现代医学， 2019，47（1）：42-44． 　　 LEI Qiao, CHEN Junjie, TIAN Jian.Correlation between the levels of F-PSA, PSA, HGH, CA15-3 and postoperative metastasis of breast cancer[J].Modern Medical Journal, 2019,47 (1): 42-44.
[2]　BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA：A Cancer Journal for Clinicians, 2018，68(6): 394-424.
[3]　万军. 血清肿瘤标志物CA153,CA125,CEA 和HER-2 联合检测在乳腺癌诊断中的价值[J]. 现代检验医学 杂志,2018,33(6):119-121. 　　 WAN Jun. Value of combined detection of tumor markers CA153,CA125,CEA and HER-2 in the diagnosis of breast cancer [J]. Journal of Modern Laboratory Medicine, 2018,33 (6): 119-121.
[4]　迪力夏提·金斯汗, 吐鲁洪·沙列尔, 赵倩. 联合检测 血清HCY,CA15-3 和FA 对乳腺癌的临床价值分析 [J]. 临床肿瘤学杂志，2016，21（6）：500-503． 　　 DILISHATI Jinsihan, TRUHON Shalieer ，ZHAO Qian. Clinical value of combined detection of serum HCY, CA15-3 and FA in patients with breast cancer[J]. Chinese Clinical Oncology, 2016,21 (6): 500-503.
[5]　唐珍．血清SCC-Ag 与CYFRA21-1 在宫颈癌患者体 内的表达水平及其联合检测的临床意义[J]．国际检 验医学杂志，2019，40（10）：1213-1215，1222. 　　 TANG Zhen. Expression levels of serum SCC-Ag and CYFRA21-1 in patients with cervical cancer and its clinical significance[J]. International Journal of Laboratory Medicine, 2019,40(10):1213-1215，1222.
[6]　中国抗癌协会乳腺癌专业委员会．中国抗癌协会乳 腺癌诊治指南与规范(2015 版)[J]．中国癌症杂志， 2015，25（9）：692-754． 　　 Chinese Anti-Cancer Association, Committee of Breast Cancer Society. Guidelines and specifications for breast cancer diagnosis and treatment of China Anti- Cancer Association (2015 edition) [J]. China Oncology, 2015,25 (9): 692-754.
[7]　　CHEN Wanqing, ZHENG Rongshou, BAADE P D, et al. Cancer statistics in China, 2015[J]. CA：A Cancer Journal for Clinicians, 2016, 66(2): 115-132.
[8]　　李卫芹，李蓉，刘佩芳，等．中国乳腺癌筛查模式 探讨[J]． 中华流行病学杂志，2016，37（7）： 1039-1043． 　　 LI Weiqin, LI Rong, LIU Peifang, et al. Discussion of breast cancer screening models in China [J]. Chinese Journal of Epidemiology, 2016,37 (7): 1039-1043.
[9]　　NISMAN B, LAFAIR J, HECHING N, et al. Evaluation of tissue polypeptide specific antigen, CYFRA 21- 1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: does the combined use of cytokeratin markers give any additional information [J]. Cancer, 2015, 82(10): 1850-1859.
[10] 何翠兰，李才元，刘翠燕，等．糖尿病伴乳腺癌患 者细胞角蛋白19 片段抗原21-1 水平的变化及其 临床意义[J]．中国糖尿病杂志，2017，25（3）： 250-254． 　　 HE Cuilan, LI Caiyuan, LIU Cuiyan, et al. Changes and clinical significance of CYFRA21-1 in diabetic patients with breast cancer [J]. Chinese Journal of Diabetes, 2017,25 (3): 250-254.
[11] SONE K, OGURI T, ITO K, et al. Predictive role of CYFRA21-1 and CEA for subsequent docetaxel in nonsmall cell lung cancer patients[J]. Anticancer Research, 2017, 37(9): 5125-5131.
[12] 王立媛，马玲，苏建荣．血清同型半胱氨酸作为肿 瘤标志物的初步探讨[J]．国际外科学杂志，2012， 39（11）：752-755． 　　 WANG Liyuan, MA Ling, SU Jianrong. Initial investigation of serum homocysteine as cancer biomarker[J]International Journal of Surgery, 2012,39 (11): 752-755.
[13] 郑丹阳， 杨志远， 李毅， 等． 血清HCY,CA15- 3,FA,VitB12 联合检测对乳腺癌女性患者病情及生存 状况的评估价值[J]．中国医药科学，2019，9（15）： 142-145． 　　 ZHENG Danyang, YANG Zhiyuan, LI Yi, et al. Evaluation value of combined detection of serum Hcy,CA15-3,FA and VitB 12 in the disease and survival of women with breast cancer [J]. China Medicine and Pharmacy, 2019,9 (15): 142-145.
[14] 王瑛，李张爱，黄华．多种肿瘤标志物联合检测在 女性乳腺癌筛查诊断中的价值[J]．中国妇幼保健， 2019，34（6）：1274-1276． 　　 WANG Ying, LI Zhang’ai, HUANG Hua. The value of combined detection of multiple tumor markers in the screening and diagnosis of breast cancer in women [J]. Maternal and Child Health Care of China, 2019,34 (6): 1274-1276.
[15] 高华， 李玉柱， 韩龙才， 等．Logistic 回 归和ROC 工作曲线评价联合检测血清 CA153,TPS,CYFRA21-1 在乳腺癌诊断中的临床价 值[J]．现代检验医学杂志，2018，33（3）：60-64. 　　 GAO Hua, LI Yuzhu, HAN Longcai, et al. Clinical Value of logistic regression and ROC work curve evaluating serum CA153,TPS and CYFRA21-1 for diagnosis of breast cancer [J]. Journal of Modern Laboratory Medicine, 2018,33 (3): 60-64.

相似文献/References:

[1]党小军,张华,王欣.人附睾蛋白4(HE4)在乳腺癌诊断中的价值[J].现代检验医学杂志,2015,30(06):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
　DANG Xiao-jun,ZHANG Hua,WANG Xin.Value of Human Epididymis Protein 4(HE4) in Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(03):84.[doi:10.3969/j.issn.1671-7414.2015.06.024]
[2]张 萍,任世云,张 雷.乳腺癌患者血清脂质运载蛋白-2 和基质金属蛋白酶-9的表达及临床意义[J].现代检验医学杂志,2015,30(01):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
　ZHANG Ping,REN Shi-yun,ZHANG Lei.Expression and Clinical Significance of Serum LCN-2 and MMP-9 in Patients with Breast Cancer[J].Journal of Modern Laboratory Medicine,2015,30(03):72.[doi:10.3969/j.issn.1671-7414.2015.01.019]
[3]乔雪峰a,黄志平b,张 宁c,等.IL-18基因启动子区-137G/C,-607G/T 2个位点基因多态性与女性乳腺癌易感性Meta分析[J].现代检验医学杂志,2016,31(04):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
　QIAO Xue-fenga,HUANG Zhi-pingb,ZHANG Ningc,et al.Association Analysis of IL-18 Gene Promoter Region -137G/C,-607G/T Polymorphisms and Susceptibility to Sporadic Breast Cancer:Meta-Analysis[J].Journal of Modern Laboratory Medicine,2016,31(03):65.[doi:10.3969/j.issn.16717-414.2016.04.017]
[4]刘延梅,马少君,张月浪,等.人类表皮生长因子受体2在乳腺癌表达与临床的相关病理特征分析[J].现代检验医学杂志,2016,31(05):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
　LIU Yan-mei,MA Shao-jun,ZHANG Yue-lang,et al.Expression of Human Epidermal Growth Factor Receptor 2 and Correlation with Clinical Pathological Features in Breast Cancer[J].Journal of Modern Laboratory Medicine,2016,31(03):91.[doi:10.3969/j.issn.1671-7414.2016.05.024]
[5]陈雨欣,谭婷婷,宁明哲.乳腺癌患者血清中白介素35(IL-35)的表达及其临床意义[J].现代检验医学杂志,2017,32(02):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
　CHEN Yu-xin,TAN Ting-ting,NING Ming-zhe.Serological Interleukin-35 Level in Patients with Breast Cancer and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2017,32(03):92.[doi:10.3969/j.issn.1671-7414.2017.02.025]
[6]唐努尔·艾尔肯,阿孜古·祖农.盐酸罗哌卡因对人乳腺癌细胞运动作用的研究[J].现代检验医学杂志,2017,32(03):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
　TANGNUER·Aierken,AZIGU·Zunong.Study on Effect of Ropivacaine on Migration of Breast Cancer Cell s[J].Journal of Modern Laboratory Medicine,2017,32(03):128.[doi:10.3969/j.issn.1671-7414.2017.03.035]
[7]靳庆娥,苏建荣.北京地区汉族女性人群SYK基因启动子区-803A>Trs290987单核苷酸多态性与乳腺癌易感性分析[J].现代检验医学杂志,2018,33(02):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　JIN Qing-e,SU Jian-rong.Associations of SYK Promoter-803A >T(rs290987)Single Nucleotide Polymorphisms with Susceptibility to Breast Cancer of Han Female Population in Beijing Area[J].Journal of Modern Laboratory Medicine,2018,33(03):5.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]高 华a,李玉柱b,韩龙才c,等.Logistic回归和ROC工作曲线评价联合检测血清CA153,TPS,CYFRA21-1在乳腺癌诊断中的临床价值[J].现代检验医学杂志,2018,33(03):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
　GAO Huaa,LI Yu-zhub,HAN Long-caic,et al.Clinical Value of Logistic Regression and ROC Work Curve Evaluating Serum CA153,TPS and Cyfra21-1 for Diagnosis of Breast Cancer[J].Journal of Modern Laboratory Medicine,2018,33(03):60.[doi:10.3969/j.issn.1671-7414.2018.03.016]
[9]李 娜a,赵晓娟b,苏晓明a.乳腺组织中SMG-1mRNA和SOX4mRNA检测在乳腺癌监测中的应用[J].现代检验医学杂志,2019,34(02):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
　LI Naa,ZHAO Xiao-juanb,SU Xiao-minga.Application of Detection of SMG-1mRNA and SOX4mRNAin Breast Tissue in Surveillance for Breast Cancer[J].Journal of Modern Laboratory Medicine,2019,34(03):35.[doi:10.3969/j.issn.1671-7414.2019.02.010]
[10]王 碧,吉茂礼.乳腺癌组织长链非编码RNA UCA1和BCAR4表达与辅助化疗效果的相关性研究[J].现代检验医学杂志,2019,34(05):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]
　WANG Bi,JI Mao-li.Correlational Research on the Expressionof Long-Chain Non-Coding RNA UCA1 and BCAR4in Breast Cancer Tissues for the Effect of Adjuvant Chemotherapy[J].Journal of Modern Laboratory Medicine,2019,34(03):77.[doi:10.3969/j.issn.1671-7414.2019.05.019]

备注/Memo

备注/Memo:
收稿日期：2019-12-13 　修回日期：2019-12-26作者简介：张维（1986-），男，硕士研究生，主管检验师，主要研究临床生化与免疫检验,E-mail: 124072968@qq.com。
更新日期/Last Update: 2020-07-20